AAVantgarde’s Post

Today, we'd like to thank Julian Zachmann at ATHOS for his support in our $141m Series B fundraise. In his words: "AAVantgarde’s platform could overcome limitations of current AAV technologies and reach underserved patients. Early clinical data suggests AAVantgarde may develop best-in-class treatments for Usher-1B and Stargardt’s disease. We’re proud to join this mission to bring next‑generation genetic medicines to patients in need and help prevent vision loss." #InheritedRetinalDiseases #AAVantgarde #SeriesB #Biotech